Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCR7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCR7 Recombinant Proteins / Extracellular Loops High purity (>95%), Endotoxin controlled. Sequence Verified. |
View CCR7 Products |
| Gene Delivery | CCR7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for GPCR conformation preservation. |
View CCR7 Products |
| Benchmark Ab | Anti-CCR7 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CCR7 Products |
| Validator | CCR7 siRNA Set For target knockdown and specificity verification. |
View CCR7 Products |
| Related Target A | CCL19 Natural high-affinity ligand for CCR7-mediated chemotaxis assays. |
View CCL19 Products |
| Related Target B | CCL21 Natural ligand driving lymph node homing and functional signaling. |
View CCL21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation Preservation | Lentivirus for Stable Cell Line development (enables cell-based flow cytometry and calcium flux) |
| Ligand Competition Screening | High-purity, sequence-verified recombinant CCL19 and CCL21 proteins (HEK293 expressed) |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CCR7/CD197 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCR7 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to bispecifics and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting lymph node metastasis prevention and hematological malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and chronic lymphocytic leukemia (CLL).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutions, Biotech Startups | T-ALL, CLL, Solid Tumor Metastasis | Flow Cytometry binding assays (Requires high-titer Lentivirus for stable CCR7 expression) |
| Bispecific Antibody / BiTE | Biopharma Innovators | Lymphoma, Refractory Leukemias | Target-binding affinity and T-cell activation (Requires recombinant CCL19/CCL21 for competition) |
| CAR-T / Cell Therapy | Clinical-stage Cell Therapy Companies | Solid Tumors (Lymph Node Homing) | Functional migration and homing assays (Requires sequence-verified CCL21 gradients) |